Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global amplicon sequencing service market size was valued at USD 700 million in 2024. The market is projected to grow from USD 750 million in 2025 to USD 1,195 million by 2032, exhibiting a CAGR of 7.7% during the forecast period.
Amplicon sequencing is a targeted next-generation sequencing (NGS) approach that focuses on specific genomic regions through PCR amplification. This technique leverages custom-designed primers to isolate and sequence predefined DNA segments, offering high sensitivity, cost-efficiency, and scalability for detecting genetic variations. Applications span microbial community analysis (16S/18S/ITS rRNA sequencing), cancer mutation profiling, inherited disease screening, and CRISPR validation studies.
Market expansion is driven by accelerating adoption in precision medicine and microbiome research, coupled with declining NGS costs. While North America currently dominates with advanced healthcare infrastructure, Asia-Pacific shows the fastest growth due to increasing biotechnology investments. Major players like Eurofins Scientific, Novogene, and Charles River Laboratories are expanding their service portfolios through strategic collaborations, such as the 2023 partnership between CD Genomics and Illumina to enhance high-throughput amplicon sequencing capabilities.
Rising Demand for Microbiome Research Accelerates Market Expansion
The global amplicon sequencing service market is experiencing robust growth driven by increasing applications in microbiome research. Microbial community analysis through 16S/18S/ITS rRNA sequencing accounts for over 40% of total amplicon sequencing applications, making it the dominant segment. This technique enables researchers to characterize complex microbial ecosystems with unprecedented resolution, fueling discoveries in human gut health, environmental microbiology, and agricultural soil analysis. The technique's cost-effectiveness compared to whole genome sequencing - typically 60-70% lower per sample - makes it particularly attractive for large-scale studies requiring high sample throughput.
Precision Medicine Adoption Creates New Demand Channels
Clinical applications in precision medicine represent the fastest-growing segment for amplicon sequencing services, projected to grow at 9.2% CAGR through 2032. The technique's ability to detect low-frequency mutations in cancer hotspots and inherited disease panels makes it invaluable for diagnostic applications. Over 300 clinical trials currently utilize amplicon sequencing for monitoring minimal residual disease or characterizing tumor heterogeneity. The technology's sensitivity in detecting variants present at frequencies as low as 0.1% provides critical advantages over traditional Sanger sequencing in therapeutic monitoring applications.
➤ The U.S. FDA has cleared multiple amplicon-based NGS tests for oncology applications, validating the clinical utility of this approach in regulated diagnostic settings.
Furthermore, the expansion of CRISPR-based therapeutics has created parallel demand for amplicon sequencing services to verify editing efficiency and detect off-target effects. The ability to multiplex hundreds of targets in a single run makes amplicon sequencing the gold standard for CRISPR validation studies.
Limitations in Multiplexing Capacity Restrain Broader Adoption
While amplicon sequencing offers numerous advantages, technical constraints around multiplexing capacity present significant adoption barriers. Current technologies typically support simultaneous analysis of 100-500 targets, which may prove insufficient for comprehensive panels in complex disease research. This limitation becomes particularly apparent in cancer genomics, where comprehensive profiling often requires analysis of thousands of genomic loci. The resulting need for multiple parallel reactions increases both costs and workflow complexity, with some studies reporting 30-40% higher reagent costs when scaling beyond 500-plex designs.
Bioinformatics Bottlenecks Slow Data Interpretation
Data analysis represents another critical challenge, with many laboratories facing difficulties in processing and interpreting amplicon sequencing results. The lack of standardized bioinformatics pipelines has led to significant variability in results between different service providers - a recent comparison showed up to 15% variation in microbial community composition reports from identical samples analyzed by different vendors. This inconsistency complicates cross-study comparisons and limits the reproducibility that is fundamental to scientific research.
Additional Technical Constraints
Primer Design Challenges
Optimal primer design remains a persistent challenge, particularly for highly polymorphic regions or when targeting novel organisms. Poor primer specificity can lead to amplification biases that distort the true biological signal, with some studies showing up to 100-fold overrepresentation of certain sequences due to preferential amplification.
Read Length Limitations
Current platforms typically generate reads of 150-300bp, which may be insufficient for differentiating closely related species in microbiome studies. This limitation forces researchers to target smaller variable regions, potentially losing phylogenetic resolution.
Emerging Applications in Food Safety Create New Growth Verticals
The food industry presents a significant growth opportunity, with food pathogen detection and authenticity testing emerging as key applications. Regulatory requirements for microbial monitoring in food production facilities are driving adoption, particularly in meat and dairy processing where contamination events can have severe public health consequences. The ability to simultaneously detect multiple pathogens from a single sample - including difficult-to-culture organisms - provides clear advantages over traditional microbiological methods.
Pharmaceutical QC Applications Offer High-Value Opportunities
Biopharmaceutical manufacturing represents another promising area, with amplicon sequencing being increasingly adopted for cell line authentication and contamination monitoring. The technology's ability to detect microbial contaminants at extremely low levels (<0.1% abundance) makes it particularly valuable for sterile manufacturing environments. Recent guidelines have started recommending NGS-based approaches for comprehensive microbial characterization of cell therapies, creating new demand from the rapidly growing advanced therapeutics sector.
➤ Several contract development and manufacturing organizations (CDMOs) have begun offering amplicon sequencing as part of their standard quality control packages for biologics production.
The agricultural biotechnology sector also shows strong potential, particularly for soil health monitoring and crop microbiome optimization. Field trials demonstrating yield improvements of 5-15% through microbiome management have spurred interest from major agribusiness firms in incorporating amplicon sequencing into their R&D pipelines.
Intense Competition Pressures Service Provider Margins
The amplicon sequencing service market has become increasingly competitive, with over 150 commercial providers globally offering similar service portfolios. This saturation has led to significant price erosion, with standard 16S sequencing costs declining by approximately 40% since 2020. Service providers face mounting pressure to differentiate through turnaround time, data quality, or value-added analysis while maintaining profitability. Many smaller players struggle to invest in the latest sequencing platforms and bioinformatics infrastructure needed to remain competitive.
Operational Challenges
Sample Logistics Complexities
The requirement for cold chain logistics for many sample types adds complexity and cost, particularly for international shipments. Some providers report sample rejection rates of 5-10% due to improper handling or delays in transit, creating operational inefficiencies.
Workforce Specialization Gaps
The interdisciplinary nature of amplicon sequencing - requiring expertise in molecular biology, bioinformatics, and specific application domains - makes talent acquisition and retention challenging. Many companies report 3-6 month lead times to fill specialized positions, constraining growth.
Regulatory Uncertainty Creates Adoption Barriers
While regulatory acceptance of NGS-based methods is growing, inconsistencies in approval pathways across regions create uncertainty for diagnostic applications. The lack of harmonized standards for validation and quality control complicates the development of regulated products incorporating amplicon sequencing data. This fragmentation is particularly evident in the IVD sector, where requirements may vary significantly between the U.S., EU, and Asian markets.
The global amplicon sequencing service market is experiencing robust growth, driven by its critical applications in microbial ecology and precision medicine. With an estimated valuation of $700 million in 2024, the market is projected to reach $1.19 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.7%. This expansion is fueled by the increasing need for highly accurate, cost-effective sequencing solutions that facilitate targeted genomic analysis. Microbial profiling using 16S/18S/ITS rRNA sequencing remains a dominant application, accounting for over 40% of market share, while cancer research and inherited disease studies are emerging as significant growth segments. The ability to detect low-frequency variants with sensitivity as high as 0.1% makes amplicon sequencing indispensable for clinical diagnostics and therapeutic development.
Integration of AI-Driven Data Analysis
The adoption of artificial intelligence (AI) in sequence data interpretation is transforming the amplicon sequencing landscape. Automated pipelines for variant calling and microbiome composition analysis reduce human error and accelerate turnaround times by up to 50%. Laboratories are increasingly deploying machine learning algorithms to identify microbial biomarkers associated with diseases like inflammatory bowel disease (IBD) and colorectal cancer, where microbiome dysbiosis plays a key role. This technological synergy enables researchers to handle massive datasets generated from multiplex PCR workflows, enhancing the scalability of large-scale epidemiological studies and clinical trials.
Agricultural biotechnology represents one of the fastest-growing application segments, with an anticipated CAGR exceeding 9% between 2024 and 2032. Amplicon sequencing is revolutionizing crop improvement programs by enabling high-throughput screening of plant-associated microbial communities and CRISPR-edited variants. Seed companies and agritech firms utilize targeted sequencing to monitor gene-editing efficiency in crops, achieving detection limits below 1% for off-target effects. Furthermore, soil microbiome analysis through ITS and 16S sequencing helps optimize fertilizer formulations, with some studies showing yield improvements of 15–20% in pilot programs. As climate-resilient crop development gains urgency, the demand for precise, scalable sequencing solutions in this sector is expected to surge.
Innovation and Strategic Expansion Drive Competition in Amplicon Sequencing
The global amplicon sequencing service market is characterized by a dynamic competitive environment where established leaders and emerging specialists compete through technological differentiation and service excellence. Eurofins Scientific currently dominates the market, leveraging its extensive global laboratory network and comprehensive genomic service portfolio to capture significant market share. The company's strength lies in its ability to deliver high-throughput sequencing with rapid turnaround times, making it a preferred partner for both academic and industrial clients.
Novogene Corporation and Charles River Laboratories have emerged as strong contenders, particularly in the Asian and North American markets respectively. These companies have gained traction through specialized offerings in microbial profiling (16S/ITS sequencing) and cancer hotspot analysis. While Novogene benefits from cost-competitive services in China's growing genomics market, Charles River enhances its position through integrated solutions that combine sequencing with downstream bioinformatics analysis.
The market also sees active participation from sequencing specialists like Zymo Research and Paragon Genomics, which focus on niche applications such as ultra-low input DNA sequencing and CRISPR editing verification. These players compete through proprietary library prep technologies that improve sequencing accuracy while reducing costs—a critical factor for research institutions operating with limited budgets. Their growth is further propelled by increasing demand for microbiome research and personalized medicine applications.
Meanwhile, CD Genomics and Psomagen are expanding their geographic footprint through strategic partnerships with regional distributors and CROs, particularly in emerging markets like Southeast Asia and the Middle East. These companies differentiate themselves by offering customized primer designs and flexible project scales, catering to diverse research needs from small academic labs to large pharmaceutical studies.
16S/18S/ITS Amplicon Sequencing Leads Due to Widespread Applications in Microbial Profiling
The market is segmented based on type into:
Precision Medicine Dominates as Amplicon Sequencing Enables Targeted Variant Detection
The market is segmented based on application into:
Academic & Research Institutes Account for Major Adoption Due to Extensive Genomic Studies
The market is segmented based on end user into:
North America
North America dominates the amplicon sequencing service market, driven by its robust healthcare infrastructure, significant R&D investments, and the presence of key industry players. The U.S. leads the region, accounting for the majority of revenue due to its advanced biotechnology sector. Precision medicine initiatives, such as the All of Us Research Program by the NIH, are accelerating demand for targeted sequencing solutions. While academic and pharmaceutical research remains a major consumer, clinical diagnostics is emerging as a high-growth segment. Challenges include high service costs and stringent data privacy regulations. However, the region's focus on personalized medicine and microbiome research ensures sustained market expansion.
Europe
Europe represents the second-largest market for amplicon sequencing services, supported by strong government funding in genomic research and tiered healthcare systems. The EU’s Horizon Europe program has allocated substantial resources toward microbial genomics and oncology, driving adoption of 16S/ITS sequencing for microbiome studies and cancer panel analyses. Countries like Germany and the U.K. are innovation hubs, with increasing public-private partnerships. Regulatory alignment under the In Vitro Diagnostic Regulation (IVDR) ensures standardized service quality but raises compliance costs for smaller providers. The agricultural biotechnology sector is also contributing to growth, particularly in pathogen detection for crop improvement.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rapid industrialization of biotech sectors and expansive healthcare investments. China, Japan, and India are frontrunners, with China’s 14th Five-Year Plan explicitly prioritizing genomic research. The region benefits from lower service costs and high-volume sequencing demand, though data analysis capabilities lag behind Western markets. Microbial ecology applications, such as soil and marine microbiome studies, are gaining traction alongside clinical uses. However, IP concerns and inconsistent regulatory frameworks remain hurdles. Collaborative initiatives like Japan’s BioBank Project are gradually unifying regional standards, positioning APAC for long-term leadership.
South America
South America’s market is nascent but exhibits potential, driven by Brazil’s and Argentina’s expanding biotechnology sectors. Research institutions increasingly adopt amplicon sequencing for infectious disease surveillance, especially for arboviruses like dengue and Zika. Limited local sequencing infrastructure necessitates reliance on international service providers, creating import dependencies. Economic instability and underfunded academic institutions slow down adoption, though partnerships with global firms (e.g., Fiocruz collaborations) are bridging gaps. Agricultural applications, particularly livestock microbiome analysis, present untapped opportunities given the region’s strong agribusiness focus.
Middle East & Africa
The MEA market is emerging unevenly, with growth concentrated in GCC nations and South Africa. Saudi Arabia’s Vision 2030 and UAE’s biotechnology incentives are fostering genomic research, particularly in inherited disease screening. High unmet clinical needs, such as antimicrobial resistance tracking, create demand but face budget constraints. Sub-Saharan Africa relies heavily on donor-funded projects like the African Microbiome Initiative, limiting commercial scalability. While the region lacks homegrown sequencing providers, outsourcing to European and Asian firms is increasing. Long-term growth hinges on localized capacity-building and public health investments.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
✅ Segmentation Analysis
✅ Regional Insights
✅ Competitive Landscape
✅ Technology & Innovation
✅ Market Dynamics
✅ Opportunities & Recommendations
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
-> The global amplicon sequencing service market size was valued at USD 700 million in 2024. The market is projected to grow from USD 750 million in 2025 to USD 1,195 million by 2032, exhibiting a CAGR of 7.7% during the forecast period.
-> Key players include Eurofins Scientific, CD Genomics, Charles River Laboratories, Psomagen, Novogene, ABM, Zymo Research, Paragon Genomics, AllGenetics, and Quintara Bio, among others. The top five players accounted for a significant market share in 2024.
-> Major growth drivers include increasing demand for precision medicine, rising applications in microbial ecology research, growing adoption in agricultural biotechnology, and technological advancements in NGS platforms.
-> North America currently leads the market due to strong biotech infrastructure, while Asia-Pacific is expected to witness the highest growth rate during the forecast period.
-> Emerging trends include automation of amplicon sequencing workflows, integration of AI for data analysis, development of ultra-high-throughput platforms, and increasing focus on microbiome research applications.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates